Baseline | Week 4 Analysis | Week 24 Analysis | |||||||
---|---|---|---|---|---|---|---|---|---|
Etanercept Group, mean (SD) | Steroid Group, mean (SD) | p* | Etanercept Group, mean (SD) | Steroid Group, mean (SD) | p* | Etanercept Group, mean (SD) | Steroid Group, mean (SD) | p* | |
Age. yrs | 58.0 (3.0) | 59.5 (2.5) | 0.7 | ||||||
Target joint pain VAS (0–100) | 65.8 (4.2) | 62.9 (3.6) | 0.6 | 39.1 (30.8) | 36.3 (23.2) | 0.97 | 41.1 (8.1) | 40.1 (8.3) | 0.9 |
DAS28 | 4.6 (0.6) | 3.7 (0.3) | 0.9 | 4.1 (1.7) | 3.6 (1.1) | 0.19 | 3.6 (2.4) | 1.9 (0.5) | 0.04 |
Target joint pain differences** | −27.9 (29.0) | −29.9 (30.1) | 0.85 | −24.7 (8.7) | −22.8 (8.8) | 0.9 | |||
ESR, mm | 32.1 (5.5) | 25.6 (5.7) | 0.4 | 32.1 (23.7) | 19.5 (17.4) | 0.19 | 36.82 (27.2) | 20.56 (15.6) | 0.18 |
Synovial thickness, mm | 9.1 (5.4) | 7.1 (5.2) | 0.3 | 8.3 (5.1) | 6.0 (0.6) | 0.16 | 8.1 (4.4) | 6.7 (4.8) | 0.4 |